A new treatment, UV corneal collagen cross-linking (CXL), has been recently introduced to reduce the progression of noninflammatory corneal degeneration such as keratoconus, pellucid marginal degeneration, and ectatic corneal disorders after corneal refractive procedures.
1-3 The treatment consists of CXL by the photosensitizer riboflavin and UV-A light preceded by corneal epithelial removal.
4